
Pharmacally
Camizestrant
Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.
Latest in Camizestrant
New Drug ApprovalAstraZeneca Camizestrant Wins FDA Approval in ESR1 Breast CancerAstraZeneca’s camizestrant has received FDA approval with a CDK4/6 inhibitor for HR-positive, HER2-negative advanced breast cancer after an emergent ESR1 mutation is detected before disease progression.Fact-Checked
Clinical TrialsAstraZeneca’s Camizestrant Extends Progression-Free Survival in SERENA-6Updated SERENA‑6 data presented at ASCO 2026 demonstrate that camizestrant combined with a CDK4/6 inhibitor delivers durable disease control in HR‑positive, HER2‑negative advanced breast cancer patients with emerging…Fact-Checked
Health TidingsFDA Panel Votes Against AstraZeneca’s Camizestrant ComboThe U.S. Food and Drug Administration’s advisory committee voted against supporting AstraZeneca’s camizestrant combination for first-line ESR1-mutant breast cancer, citing benefit–risk uncertainty despite strong SERENA-6 results showing improved…Fact-Checked
Explore more
Health TidingsIndustry, pipeline and company news.
RegulatoryApprovals, policy and agency decisions.
ResearchPeer-reviewed studies and scientific breakthroughs.
Drug FinderLook up any drug: uses, dosing and safety.
From the HistoryLandmark moments in pharmaceutical history.
LatestEvery new story, as soon as it is published.